Bai Bingjun, Xie Shangzhi, Wang Ya, Wu Fei, Chen Yao, Bian Jia, Gao Xing
Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Institute of Genomic Medicine, Wenzhou Medical University, Wenzhou, China.
Front Mol Biosci. 2024 Dec 9;11:1463061. doi: 10.3389/fmolb.2024.1463061. eCollection 2024.
This review provides an in-depth summary of the development of anti-cancer drugs for tumor-associated macrophages (TAMs), with a particular focus on the development and tissue specialization of macrophages, and factors influencing the polarization of M1 and M2 macrophages, and mechanistic insights underlying the targeting therapeutic approaches. TAMs, pivotal in the tumor microenvironment, exhibit notable plasticity and diverse functional roles. Influenced by the complex milieu, TAMs polarize into M1-type, which suppresses tumors, and M2-type, which promotes metastasis. Notably, targeting M2-TAMs is a promising strategy for tumor therapy. By emphasizing the importance of macrophages as a therapeutic target of anti-cancer drugs, this review aims to provide valuable insights and research directions for clinicians and researchers.
本综述深入总结了针对肿瘤相关巨噬细胞(TAM)的抗癌药物的发展情况,特别关注巨噬细胞的发育和组织特异性,影响M1和M2巨噬细胞极化的因素,以及靶向治疗方法的潜在机制。TAM在肿瘤微环境中起关键作用,具有显著的可塑性和多种功能作用。受复杂微环境的影响,TAM极化为抑制肿瘤的M1型和促进转移的M2型。值得注意的是,靶向M2-TAM是一种有前景的肿瘤治疗策略。通过强调巨噬细胞作为抗癌药物治疗靶点的重要性,本综述旨在为临床医生和研究人员提供有价值的见解和研究方向。